352 results match your criteria: "University of Burgundy Franche Comte[Affiliation]"
Nat Med
January 2025
Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Genetic diagnosis of rare diseases requires accurate identification and interpretation of genomic variants. Clinical and molecular scientists from 37 expert centers across Europe created the Solve-Rare Diseases Consortium (Solve-RD) resource, encompassing clinical, pedigree and genomic rare-disease data (94.5% exomes, 5.
View Article and Find Full Text PDFCancer Chemother Pharmacol
December 2024
Pharmacy Department, Centre Georges-François Leclerc, Dijon, France.
Objectives: The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement is subject to variations, that may lead to unnecessary dosage reductions and therefore to a reduced efficacy of treatment. Recently, new factors such as hepatic and renal impairment have been proposed as also influencing uracil concentration.
View Article and Find Full Text PDFJCO Oncol Pract
December 2024
Marie-Christine Etienne-Grimaldi, PhD, PharmD, Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France; Bernard Royer, PhD, PharmD, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon and Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Besançon, France; Manon Launay, PhD, PharmD, Institut Curie, Service de Pharmacologie, Saint-Cloud, France; Antonin Schmitt, PhD, PharmD, Pharmacy Department, Centre Georges-François Leclerc, Dijon and INSERM U1231, University of Burgundy Franche-Comté, Dijon, France; Fabienne Thomas, PhD, PharmD, Oncopole Claudius Regaud, Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm, Toulouse, France; and Joseph Ciccolini, PhD, PharmD, COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 and University Hospital of Marseille, Marseille, France.
J Stomatol Oral Maxillofac Surg
November 2024
Department of Maxillofacial, Plastic-Reconstructive and Aesthetic Surgery, Hand Surgery, University Hospital of Dijon, Boulevard de Maréchal-de-Lattre-de-Tassigny, Dijon 21000, France.
Future Oncol
November 2024
Department of Medical Oncology, Center GF Leclerc, Dijon, France.
Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy. This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.
View Article and Find Full Text PDFEur Respir J
November 2024
Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, réseau OrphaLung, Filière RespiFil, Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France
Background: Drug-induced interstitial lung disease (DI-ILD) is a heterogeneous subgroup of interstitial lung diseases (ILD). The number of molecules involved is increasing with time. Due to their low incidence, DI-ILDs may be detected only after a drug has been marketed, notably through Adverse Drug Reaction (ADR) reports to pharmacovigilance centres.
View Article and Find Full Text PDFThe TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real-world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty-one (49%) of the CP-CML patients were in third line of treatment.
View Article and Find Full Text PDFSports (Basel)
October 2024
Laboratory of Psy-Drepi (EA 7428), University of Burgundy-Franche-Comté, Maison de l'université, Esplanade Erasme, BP 27877, CEDEX, 21078 Dijon, France.
The aims of this study were: (a) to explore the relationships between adaptive defense mechanisms (ADMs), maladaptive defense mechanisms (MADMs), stress, recovery, resilience, and sport burnout; and (b) to examine resilience, stress, and recovery as mediators of the relationship between defense mechanisms and burnout. One hundred and seventy-five athletes ( = 20.30 years, = 3.
View Article and Find Full Text PDFMar Drugs
September 2024
Laboratory of Marine Biochemistry and Ecotoxicology, Department of Earth and Marine Sciences DiSTeM, University of Palermo, Via Barlotta 4, 91100 Trapani, Italy.
The blue crab (), originally from the western Atlantic Ocean, has recently spread to the Mediterranean and is now considered one of the one hundred most invasive species in that region. This opportunistic species, known for its adaptability to different temperatures and salinities, negatively impacts biodiversity and human activities such as fishing and tourism in the Mediterranean. However, the blue crab is gaining interest as a potential food resource due to its high nutritional value and delicate, sweet flavor.
View Article and Find Full Text PDFCancers (Basel)
September 2024
Platform of Transfer in Biological Oncology, Georges-Francois Leclerc Cancer Center-UNICANCER, 21000 Dijon, France.
Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. This study investigates the clinical interest of whole exome sequencing (WES) for analyzing somatic mutational signatures in patients with advanced or metastatic NSCLC treated with the current standard of care.
Methods: Exome sequencing data and clinical characteristics from 132 patients with advanced or metastatic NSCLC were analyzed.
Anxiety Stress Coping
August 2024
Laboratory of Psy-Drepi, University of Burgundy-Franche-Comté, Dijon, France.
Objectives: This study explored whether several subgroups of athletes representing distinct trajectories of intensity and direction of pleasant and unpleasant emotions (anger, anxiety, dejection, excitement, and happiness) could be shown to exist within the latent growth analysis (LCGA). A secondary objective was to examine whether athletes belonging to distinct trajectories of intensity and direction of emotions reported distinct scores of adaptive defense mechanisms (ADM) and maladaptive defense mechanisms (MDM).
Design: A longitudinal four-wave measurement design was used in the present study.
J Clin Oncol
October 2024
Moores Cancer Center, UC San Diego, La Jolla, CA.
Purpose: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available.
Methods: We trained DeepHRD, a deep learning platform for predicting HRD from hematoxylin and eosin (H&E)-stained histopathological slides, using primary breast (n = 1,008) and ovarian (n = 459) cancers from The Cancer Genome Atlas (TCGA).
Cancers (Basel)
May 2024
Unit of Pathology, Department of Tumor Biology and Pathology, Georges-François Leclerc Cancer Center, 21000 Dijon, France.
Background: With the development of some new antibody-drug conjugates, the HER2 classification of breast carcinomas now includes the HER2-low (H2L) category: IHC 1+, 2+ non-amplified by ISH, and double-equivocal carcinomas, mostly luminal, expressing hormone receptors (HR+).
Methods: We analyzed mutational status and transcriptomic activities of three HER2 effector pathways: PI3K-AKT, MAPK, and JAK-STAT, in association with clinicopathologic features, in 62 H2L carcinomas compared to 43 HER2-positive and 20 HER2-negative carcinomas, all HR+.
Results: H2L carcinomas had significantly lower histoprognostic grades and mitotic and Ki67 proliferation indexes than HER2-positive carcinomas.
EBioMedicine
July 2024
Centre de Recherche INSERM LNC-UMR1231, Dijon, France; Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France; Genetic and Immunology Medical Institute, Dijon, France; University of Burgundy Franche-Comté, Dijon, France; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. Electronic address:
Background: T-cell immune infiltrates are robust prognostic variables in localised colon cancer. Evaluation of prognosis using artificial intelligence is an emerging field. We evaluated whether machine learning analysis improved prediction of patient outcome in comparison with analysis of T cell infiltrate only or in association with clinical variables.
View Article and Find Full Text PDFPLoS One
June 2024
Laboratory of Muscle and Tendon Plasticity, Graduate Program of Physical Education, University of Brasília, Brasília, Distrito Federal, Brazil.
Nat Med
August 2024
Hematology, University Hospital Inserm U-S1277 and CNRS UMR9020, Lille, France.
Eur Urol Oncol
December 2024
Biopathologie et Génétique des Cancers, Institut Médical d'Analyse Génomique, Imagenome, Inovie, Montpellier, France; Unité de Recherche Clinique, Clinique Beausoleil, Montpellier, France. Electronic address:
Background And Objective: Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa.
View Article and Find Full Text PDFArch Cardiovasc Dis
June 2024
Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), French Alliance for Cardiovascular Trials, Hôpital Saint-Antoine, AP-HP, Sorbonne University, 75012 Paris, France.
Background: Despite major advances in prevention and treatment, cardiovascular diseases - particularly acute myocardial infarction - remain a leading cause of death worldwide and in France. Collecting contemporary data about the characteristics, management and outcomes of patients with acute myocardial infarction in France is important.
Aims: The main objectives are to describe baseline characteristics, contemporary management, in-hospital and long-term outcomes of patients with acute myocardial infarction hospitalized in tertiary care centres in France; secondary objectives are to investigate determinants of prognosis (including periodontal disease and sleep-disordered breathing), to identify gaps between evidence-based recommendations and management and to assess medical care costs for the index hospitalization and during the follow-up period.
Eur J Hum Genet
September 2024
FHU TRANSLAD, GAD INSERM UMR 1231, University of Burgundy, Dijon, France.
Generation and subsequently accessibility of secondary findings (SF) in diagnostic practice is a subject of debate around the world and particularly in Europe. The French FIND study has been set up to assess patient/parent expectations regarding SF from exome sequencing (ES) and to collect their real-life experience until 1 year after the delivery of results. 340 patients who had ES for undiagnosed developmental disorders were included in this multicenter mixed study (quantitative N = 340; qualitative N = 26).
View Article and Find Full Text PDFAnn Pharm Fr
September 2024
Department of Pharmacy, University Hospital and EPICAD LNC UMR 1231, University of Burgundy & Franche Comte, Dijon, France. Electronic address:
Objective: Cardiovascular risk is increased in patients with diabetes. Little is known about glycemic and lipid control in patients with diabetes. We aimed to assess glycemic and lipid controls in patients with diabetes at time of their myocardial infarction.
View Article and Find Full Text PDFTher Adv Med Oncol
April 2024
Pharmacy Department, Centre Georges-François Leclerc, 1 rue Pr Marion, Dijon 21079, France.
Clin Cancer Res
July 2024
Department of Digestive and Endocrine Surgery, Dijon University Hospital, Dijon, France.
Eur J Cancer
May 2024
Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; University of Burgundy-Franche Comté, 21000 Dijon, France; INSERM U1231, 21000 Dijon, France. Electronic address:
J Oncol Pharm Pract
March 2024
Department of Pharmacy, University Hospital and EPICAD LNC UMR 1231, University of Burgundy & Franche Comte, Dijon, France.
Introduction: The increasing number of oral anticancer medicines (OAMs) dispensed in community pharmacies and the associated challenges (misuse, management of side effects) give the community pharmacist (CP) a major role in the pharmacotherapeutic management of cancer patients. In France, as a response to these challenges, cancer outpatients can schedule a meeting with their CP to ensure the safe and effective use of OAMs. The objectives of this study were to evaluate the perspectives of these interventions regarding their implementation and the opinion of French CPs.
View Article and Find Full Text PDFJ Gynecol Obstet Hum Reprod
May 2024
Department of Surgical Oncology, Georges François Leclerc Cancer Center -UNICANCER, Dijon, France; University of Burgundy-Franche Comté, Dijon, France.
Introduction: Patients with BRCA1/2 mutations have a higher risk of developing breast cancer compared to the wild-type population. For patients with a BRCA mutation, there are no specific recommendations for surgical management. The aim of this study was therefore to retrospectively investigate overall survival (OS) and recurrence-free survival (RFS) of BRCA mutated patients with localized invasive breast cancer, by comparing conservative surgery versus mastectomy.
View Article and Find Full Text PDF